Evan Seigerman
Stock Analyst at BMO Capital
(4.12)
# 542
Out of 5,112 analysts
152
Total ratings
55.45%
Success rate
12.24%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Outperform | $35 → $54 | $39.82 | +35.61% | 3 | Dec 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,100 → $1,200 | $1,056.88 | +13.54% | 10 | Dec 4, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $120 → $130 | $121.47 | +7.02% | 18 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $447.38 | +18.47% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $97.31 | -38.34% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $90.44 | +32.68% | 6 | May 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $141.84 | -18.92% | 15 | May 6, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $169.91 | -18.19% | 27 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $53.33 | +14.38% | 11 | Nov 12, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $62.45 | -35.95% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $40 | $9.69 | +312.80% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $748.71 | +5.25% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $8.99 | -72.19% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $324.42 | -25.10% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $5.54 | +116.61% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $25.04 | +139.62% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.57 | +1,810.83% | 3 | May 12, 2020 |
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $35 → $54
Current: $39.82
Upside: +35.61%
Eli Lilly and Company
Dec 4, 2025
Maintains: Outperform
Price Target: $1,100 → $1,200
Current: $1,056.88
Upside: +13.54%
Gilead Sciences
Aug 8, 2025
Maintains: Outperform
Price Target: $120 → $130
Current: $121.47
Upside: +7.02%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $447.38
Upside: +18.47%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $97.31
Upside: -38.34%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $90.44
Upside: +32.68%
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $141.84
Upside: -18.92%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $169.91
Upside: -18.19%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $53.33
Upside: +14.38%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $62.45
Upside: -35.95%
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $9.69
Upside: +312.80%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $748.71
Upside: +5.25%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $8.99
Upside: -72.19%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $324.42
Upside: -25.10%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $5.54
Upside: +116.61%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $25.04
Upside: +139.62%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.57
Upside: +1,810.83%